dc.contributor.author |
Showalter, HD |
en |
dc.contributor.author |
Denny, William |
en |
dc.date.accessioned |
2011-11-17T17:13:22Z |
en |
dc.date.issued |
2008 |
en |
dc.identifier.citation |
Tuberculosis 88(Supplement 1):S3-S17 2008 |
en |
dc.identifier.issn |
1472-9792 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/9213 |
en |
dc.description.abstract |
Summary Drug discovery and development, from an initial disease treatment concept to a new drug application (NDA), is a complex, lengthy and expensive process. In this review we discuss the key stages of drug discovery and early development, including target identification and validation, assay development and screening, confirmed hits to leads, lead optimization, and progressing development candidates to an investigational new drug (IND) filing. We also provide particular examples of how this process is beginning to assist in the development of small molecule treatments for tuberculosis, by summarizing the status of the clinical development of several newer classes of drugs. These include the fluoroquinolones, oxazolidinones, diarylquinolines, and nitroimidazo-oxazoles and -oxazines. |
en |
dc.language |
EN |
en |
dc.publisher |
Elsevier Ltd. |
en |
dc.relation.ispartofseries |
Tuberculosis |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. Details obtained from
http://www.sherpa.ac.uk/romeo/issn/1472-9792/ |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.subject |
tuberculosis |
en |
dc.subject |
Mycobacterium tuberculosis |
en |
dc.subject |
drug discovery |
en |
dc.subject |
fluoroquinolones |
en |
dc.subject |
oxazolidinones |
en |
dc.subject |
diarylquinolines |
en |
dc.subject |
nitroimidazooxazoles |
en |
dc.subject |
nitroimidazooxazines |
en |
dc.subject |
SUBSTANCE OFLOXACIN DL8280 |
en |
dc.subject |
IN-VITRO ACTIVITIES |
en |
dc.subject |
MYCOBACTERIUM-TUBERCULOSIS |
en |
dc.subject |
DNA GYRASE |
en |
dc.subject |
PULMONARY TUBERCULOSIS |
en |
dc.subject |
ANTITUBERCULOSIS ACTIVITY |
en |
dc.subject |
ANTIMICROBIAL AGENTS |
en |
dc.subject |
MURINE TUBERCULOSIS |
en |
dc.subject |
LEAD OPTIMIZATION |
en |
dc.subject |
ATP SYNTHASE |
en |
dc.title |
A roadmap for drug discovery and its translation to small molecule agents in clinical development for tuberculosis treatment. |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1016/S1472-9792(08)70032-5 |
en |
pubs.issue |
Supplement 1 |
en |
pubs.begin-page |
S3 |
en |
pubs.volume |
88 |
en |
dc.rights.holder |
Copyright: 2008 Elsevier Ltd. |
en |
dc.identifier.pmid |
18762151 |
en |
pubs.end-page |
S17 |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Review |
en |
pubs.elements-id |
79521 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
Medical Sciences |
en |
pubs.org-id |
Auckland Cancer Research |
en |
pubs.org-id |
Science |
en |
pubs.org-id |
Science Research |
en |
pubs.org-id |
Maurice Wilkins Centre (2010-2014) |
en |
pubs.record-created-at-source-date |
2010-09-01 |
en |
pubs.dimensions-id |
18762151 |
en |